Lung function trajectories in patients with idiopathic pulmonary fibrosis

被引:7
作者
Neely, Megan L. [1 ,2 ]
Hellkamp, Anne S. [1 ,2 ]
Bender, Shaun [3 ]
Todd, Jamie L. [1 ,2 ]
Liesching, Timothy [4 ]
Luckhardt, Tracy R. [5 ]
Oldham, Justin M. [6 ]
Raj, Rishi [7 ]
White, Eric S. [3 ]
Palmer, Scott M. [1 ,2 ]
机构
[1] Duke Clin Res Inst, Durham, NC 27701 USA
[2] Duke Univ, Med Ctr, Durham, NC 27710 USA
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[4] Lahey Hosp & Med Ctr, Burlington, MA USA
[5] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA
[6] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[7] Stanford Univ, Sch Med, Stanford, CA USA
关键词
Interstitial lung disease; Lung function testing; Forced vital capacity; FORCED VITAL CAPACITY; CLINICAL-COURSE; INTERSTITIAL PNEUMONIA; SURVIVAL; PROGRESSION; MORTALITY; PIRFENIDONE; SPIROMETRY; NINTEDANIB; EFFICACY;
D O I
10.1186/s12931-023-02503-5
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF.Methods Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed prospectively, with lung function data collected as part of routine clinical care. Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such as disease severity and visit patterns. Results Of 1002 patients in the registry, 941 had = 1 FVC and/or DLco measurement after enrolment. The median (Q1, Q3) follow-up period was 35.1 (18.9, 47.2) months. Overall, mean estimated declines in FVC and DLco % predicted were 2.8% and 2.9% per year, respectively. There was no evidence that the mean trajectories of FVC or DLco had a non-linear relationship with time at the population level. Patients who were male, white, had a family history of ILD, were using oxygen, or had prior/current use of antifibrotic therapy at enrolment had greater rates of decline in FVC % predicted. Patients who were male or white had greater rates of decline in DLco % predicted.Conclusions Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF. A graphical abstract summarising the data in this manuscript is available at: https://www.usscicomms.com/respiratory/IPF-PRORegistry_LungFunctionTrajectories.
引用
收藏
页数:10
相关论文
共 44 条
[11]   Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort [J].
Fainberg, Hernan P. ;
Oldham, Justin M. ;
Molyneaux, Philip L. ;
Allen, Richard J. ;
Kraven, Luke M. ;
Fahy, William A. ;
Porte, Joanne ;
Braybrooke, Rebecca ;
Saini, Gauri ;
Karsdal, Morten A. ;
Leeming, Diane J. ;
Sand, Jannie M. B. ;
Triguero, Isaac ;
Oballa, Eunice ;
Wells, Athol U. ;
Renzoni, Elisabetta ;
Wain, Louise, V ;
Noth, Imre ;
Maher, Toby M. ;
Stewart, Iain D. ;
Jenkins, R. Gisli .
LANCET DIGITAL HEALTH, 2022, 4 (12) :E862-E872
[12]   Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry [J].
Gao, Jing ;
Kalafatis, Dimitrios ;
Carlson, Lisa ;
Pesonen, Ida H. A. ;
Li, Chuan-Xing ;
Wheelock, Asa ;
Magnusson, Jesper M. ;
Skold, C. Magnus .
RESPIRATORY RESEARCH, 2021, 22 (01)
[13]   Sex differences in physiological progression of idiopathic pulmonary fibrosis [J].
Han, M. K. ;
Murray, S. ;
Fell, C. D. ;
Flaherty, K. R. ;
Toews, G. B. ;
Myers, J. ;
Colby, T. V. ;
Travis, W. D. ;
Kazerooni, E. A. ;
Gross, B. H. ;
Martinez, F. J. .
EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (06) :1183-1188
[14]   Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis [J].
Hook, J. L. ;
Arcasoy, S. M. ;
Zemmel, D. ;
Bartels, M. N. ;
Kawut, S. M. ;
Lederer, D. J. .
EUROPEAN RESPIRATORY JOURNAL, 2012, 39 (02) :359-365
[15]   Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry [J].
Jo, Helen E. ;
Glaspole, Ian ;
Moodley, Yuben ;
Chapman, Sally ;
Ellis, Samantha ;
Goh, Nicole ;
Hopkins, Peter ;
Keir, Greg ;
Mahar, Annabelle ;
Cooper, Wendy ;
Reynolds, Paul ;
Walters, E. Haydn ;
Zappala, Christopher ;
Grainge, Christopher ;
Allan, Heather ;
Macansh, Sacha ;
Corte, Tamera J. .
BMC PULMONARY MEDICINE, 2018, 18
[16]   Forced Vital Capacity in Idiopathic Pulmonary Fibrosis - FDA Review of Pirfenidone and Nintedanib [J].
Karimi-Shah, Banu A. ;
Chowdhury, Badrul A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (13) :1189-1191
[17]   Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry [J].
Kim, Hyun J. ;
Snyder, Laurie D. ;
Neely, Megan L. ;
Hellkamp, Anne S. ;
Hotchkin, David L. ;
Morrison, Lake D. ;
Bender, Shaun ;
Leonard, Thomas B. ;
Culver, Daniel A. .
LUNG, 2022, 200 (01) :21-29
[18]   Hospitalizations in patients with idiopathic pulmonary fibrosis [J].
Kim, Hyun J. ;
Snyder, Laurie D. ;
Adegunsoye, Ayodeji ;
Neely, Megan L. ;
Bender, Shaun ;
White, Eric S. ;
Conoscenti, Craig S. ;
Strek, Mary E. .
RESPIRATORY RESEARCH, 2021, 22 (01)
[19]   A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis [J].
King, Talmadge E., Jr. ;
Bradford, Williamson Z. ;
Castro-Bernardini, Socorro ;
Fagan, Elizabeth A. ;
Glaspole, Ian ;
Glassberg, Marilyn K. ;
Gorina, Eduard ;
Hopkins, Peter M. ;
Kardatzke, David ;
Lancaster, Lisa ;
Lederer, David J. ;
Nathan, Steven D. ;
Pereira, Carlos A. ;
Sahn, Steven A. ;
Sussman, Robert ;
Swigris, Jeffrey J. ;
Noble, Paul W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2083-2092
[20]   Fibrotic idiopathic interstitial pneumonia - The prognostic value of longitudinal functional trends [J].
Latsi, PI ;
du Bois, RM ;
Nicholson, AG ;
Colby, TV ;
Bisirtzoglou, D ;
Nikolakopoulou, A ;
Veeraraghavan, S ;
Hansell, DM ;
Wells, AU .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (05) :531-537